Aclarion, Inc. (ACONW) stock analysis
From the 10-K filed 2026-03-18
Business type: Asset play
How it makes money
It earns by licensing diagnostic software to imaging centers, with revenue scaling based on physician adoption and insurance reimbursement status.
It provides a Software-as-a-Service (SaaS) platform called Nociscan that processes data from standard MRI machines to identify chemical markers of disc pain. Because it currently lacks broad insurance coverage, its revenue growth depends on convincing clinicians and surgeons to use the tool and successfully converting temporary medical billing codes into permanent, reimbursable codes.
What protects it: the moat
Its defense rests on exclusive licensing of UCSF biomarkers and a portfolio of 28 U.S. patents.
The company relies on intellectual property to prevent competitors from replicating its diagnostic algorithms. It claims a competitive edge by using proprietary signal processing that turns raw magnetic resonance data into actionable biomarkers, though it acknowledges that the success of these protections is subject to maintaining compliance with the FDA and other regulatory bodies.
What growth costs
It must continuously fund clinical trials, regulatory compliance, and sales efforts to secure reimbursement and physician referrals.
Because the product is diagnostic, the company incurs heavy costs to conduct studies that prove its value to medical societies and insurers. It also spends significant resources hiring sales and marketing personnel to build a network of imaging centers, as adoption is currently low and requires active physician education.
What could damage it
The loss of insurance reimbursement eligibility would destroy the economic viability of its diagnostic software.
The company depends on third-party payers to cover the cost of the Nociscan procedure. If insurers decide the evidence for its technology is insufficient or if the company fails to convert its temporary billing codes into permanent, adequately reimbursed codes, it loses the primary mechanism by which imaging centers and surgeons justify using the software, effectively terminating its path to profitability.
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.